ENTA
Price
$17.46
Change
+$0.93 (+5.63%)
Updated
Mar 28, 6:59 PM EST
38 days until earnings call
EXEL
Price
$23.73
Change
-$0.13 (-0.54%)
Updated
Mar 28, 6:59 PM EST
39 days until earnings call
Ad is loading...

Compare predictions ENTA vs EXEL

Header iconENTA vs EXEL Comparison
Open Charts ENTA vs EXELBanner chart's image
Enanta Pharmaceuticals
Price$17.46
Change+$0.93 (+5.63%)
Volume$189.49K
CapitalizationN/A
Exelixis
Price$23.73
Change-$0.13 (-0.54%)
Volume$1.31M
CapitalizationN/A
View a ticker or compare two or three
ENTA vs EXEL Comparison Chart

Loading...

ENTADaily Signal changed days agoGain/Loss if shorted
 
Show more...
EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ENTA vs. EXEL commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Buy and EXEL is a Buy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (ENTA: $17.43 vs. EXEL: $23.73)
Brand notoriety: ENTA: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 120% vs. EXEL: 92%
Market capitalization -- ENTA: $368.75M vs. EXEL: $7.19B
ENTA [@Biotechnology] is valued at $368.75M. EXEL’s [@Biotechnology] market capitalization is $7.19B. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileEXEL’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • EXEL’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than EXEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 5 TA indicator(s) are bullish while EXEL’s TA Score has 5 bullish TA indicator(s).

  • ENTA’s TA Score: 5 bullish, 4 bearish.
  • EXEL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than EXEL.

Price Growth

ENTA (@Biotechnology) experienced а +19.14% price change this week, while EXEL (@Biotechnology) price change was -0.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

ENTA is expected to report earnings on May 06, 2024.

EXEL is expected to report earnings on May 07, 2024.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ENTA with price predictions.
OPEN
A.I.dvisor published
a Summary for EXEL with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EXEL($7.2B) has a higher market cap than ENTA($369M). ENTA YTD gains are higher at: 85.228 vs. EXEL (-1.084). EXEL has higher annual earnings (EBITDA): 197M vs. ENTA (-124.91M). EXEL has more cash in the bank: 995M vs. ENTA (337M). ENTA has less debt than EXEL: ENTA (25.5M) vs EXEL (190M). EXEL has higher revenues than ENTA: EXEL (1.83B) vs ENTA (73.6M).
ENTAEXELENTA / EXEL
Capitalization369M7.2B5%
EBITDA-124.91M197M-63%
Gain YTD85.228-1.084-7,864%
P/E RatioN/A36.51-
Revenue73.6M1.83B4%
Total Cash337M995M34%
Total Debt25.5M190M13%
FUNDAMENTALS RATINGS
ENTA vs EXEL: Fundamental Ratings
ENTA
EXEL
OUTLOOK RATING
1..100
8118
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10091
SMR RATING
1..100
9775
PRICE GROWTH RATING
1..100
3749
P/E GROWTH RATING
1..100
157
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (75) in the Biotechnology industry is in the same range as ENTA (95). This means that EXEL’s stock grew similarly to ENTA’s over the last 12 months.

EXEL's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as ENTA (100). This means that EXEL’s stock grew similarly to ENTA’s over the last 12 months.

EXEL's SMR Rating (75) in the Biotechnology industry is in the same range as ENTA (97). This means that EXEL’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (37) in the Biotechnology industry is in the same range as EXEL (49). This means that ENTA’s stock grew similarly to EXEL’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for EXEL (57). This means that ENTA’s stock grew somewhat faster than EXEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAEXEL
RSI
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
63%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 5 days ago
76%
MACD
ODDS (%)
Bullish Trend 1 day ago
67%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
70%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
67%
Advances
ODDS (%)
Bullish Trend 1 day ago
67%
Bullish Trend 9 days ago
65%
Declines
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 4 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
70%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
65%
View a ticker or compare two or three
Ad is loading...
ENTADaily Signal changed days agoGain/Loss if shorted
 
Show more...
EXELDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IAT43.380.40
+0.93%
iShares US Regional Banks ETF
FSMD38.860.20
+0.52%
Fidelity Small-Mid Multifactor ETF
RHTX15.040.06
+0.43%
RH Tactical Outlook ETF
IBB137.22-0.57
-0.41%
iShares Biotechnology ETF
DUST9.34-0.42
-4.30%
Direxion Daily Gold Miners Bear 2X ETF

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with CHRS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then CHRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+5.44%
CHRS - ENTA
40%
Loosely correlated
-1.65%
ORMP - ENTA
35%
Loosely correlated
+3.55%
XNCR - ENTA
34%
Loosely correlated
-1.43%
AXON - ENTA
34%
Loosely correlated
-0.98%
PRME - ENTA
34%
Loosely correlated
+3.48%
More

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with RVMD. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
-0.54%
RVMD - EXEL
37%
Loosely correlated
+1.51%
SRPT - EXEL
36%
Loosely correlated
-0.57%
INCY - EXEL
36%
Loosely correlated
-0.30%
ALNY - EXEL
34%
Loosely correlated
-3.24%
ADMA - EXEL
34%
Loosely correlated
-2.08%
More